Paul M Beringer
Overview
Explore the profile of Paul M Beringer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
253
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hong E, Beringer P
CPT Pharmacometrics Syst Pharmacol
. 2024 Mar;
13(4):509-510.
PMID: 38511610
No abstract available.
2.
Hong E, Zampoli M, Beringer P
Clin Pharmacol Ther
. 2024 Feb;
115(6):1204-1207.
PMID: 38385853
No abstract available.
3.
Shi A, Nguyen H, Kuo C, Beringer P
J Cyst Fibros
. 2024 Jan;
23(3):566-572.
PMID: 38233246
Introduction: The efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ETI) have been established in prospective clinical trials. Liver function test elevations were observed in a greater proportion of patients receiving ETI compared...
4.
Hong E, Parsons S, Sass L, Epstein C, Chan L, Brown C, et al.
J Cyst Fibros
. 2023 Nov;
23(3):519-523.
PMID: 38036321
The concomitant use of elexacaftor/tezacaftor/ivacaftor (ETI) and strong CYP3A inducers including rifampin and rifabutin is not recommended due to the risk of drug-drug interactions (DDI). This presents a significant challenge...
5.
Hong E, Carmanov E, Shi A, Chung P, Rao A, Forrester K, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242680
Elexacaftor/tezacaftor/ivacaftor (ETI) treatment has potential benefits in lung transplant recipients, including improvements in extrapulmonary manifestations, such as gastrointestinal and sinus disease; however, ivacaftor is an inhibitor of cytochrome P450 3A...
6.
Hong E, Li R, Shi A, Almond L, Wang J, Khudari A, et al.
Pharmacotherapy
. 2023 Mar;
43(4):291-299.
PMID: 36866442
Introduction: Elexacaftor/tezacaftor/ivacaftor (ETI) treatment is associated with significant improvement in lung function in people with cystic fibrosis (pwCF); however, some patients experience adverse effects (AEs) including hepatotoxicity. One potential strategy...
7.
Hong E, Almond L, Chung P, Rao A, Beringer P
Clin Pharmacol Ther
. 2022 Mar;
111(6):1324-1333.
PMID: 35292968
Cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, including elexacaftor-tezacaftor-ivacaftor, are primarily eliminated through cytochrome P450 (CYP) 3A-mediated metabolism. This creates a therapeutic challenge to the treatment of coronavirus disease...
8.
Park A, Tran D, Schaal J, Wang M, Selsted M, Beringer P
Antimicrob Agents Chemother
. 2022 Jan;
66(3):e0212521.
PMID: 35041507
Severe illness caused by coronavirus disease 2019 (COVID-19) is characterized by an overexuberant inflammatory response resulting in acute respiratory distress syndrome (ARDS) and progressive respiratory failure (A. Gupta, M. V....
9.
Chaudhuri D, Ganesan R, Vogelaar A, Dughbaj M, Beringer P, Camarero J
J Org Chem
. 2021 Oct;
86(21):15242-15246.
PMID: 34641669
Classical approaches for the backbone cyclization of polypeptides require conditions that may compromise the chirality of the C-terminal residue during the activation step of the cyclization reaction. Here, we describe...
10.
Dughbaj M, Jayne J, Park A, Bensman T, Algorri M, Ouellette A, et al.
Antibiotics (Basel)
. 2021 Sep;
10(9).
PMID: 34572625
Vicious cycles of chronic airway obstruction, lung infections with , and neutrophil-dominated inflammation contribute to morbidity and mortality in cystic fibrosis (CF) patients. Rhesus theta defensin-1 (RTD-1) is an antimicrobial...